Stakeholders will get a chance to sound off on the Food and Drug Administration (FDA)'s proposal to raise device user fees in exchange for shorter review times.
Â
The agency will hold a public workshop on March 28, 2012Â in Washington, D.C. on the reauthorization of the medical device user fee program.
The FDA reached a preliminary deal with manufacturers in February to collect $595 million in fees for device applications over the next five years. Thats roughly double what the agency has collected over the past five years, and industry officials agreed to the increase in exchange for improvements in the device review process.
For example, the FDA agreed to hire more than 200 full-time workers by the end of the five-year program, and interact with companies earlier in the submission process.
In terms of specifics, for a 510(k) application, a device maker would pay 2 percent of the fee for a premarket approval (PMA) application, up from 1.84 percent, according to draft legislative language.
 Â
The agreement with FDA enhances both the predictability and transparency of the agency, says Lindsay Morris, senior director of government relations for the Medical Imaging and Technology Alliance, an imaging technology trade association based in Arlington, Va. In a time of tremendous advances in imaging and radiation therapy technologies, the agreement enables the industry to bring innovative, life-saving technologies to market faster, so that patients receive the care they need.
After considering the comments, the FDA will send a final proposal to Congress, which must decide by Sept. 30 whether to reauthorize the program or let it expire.
Source: AAMI
Unmasking Vaccine Myths: Dr Marschall Runge on Measles, Misinformation, and Public Health Solutions
May 29th 2025As measles cases climb across the US, discredited myths continue to undercut public trust in vaccines. In an exclusive interview with Infection Control Today, Michigan Medicine’s Marschall Runge, PhD, confronts misinformation head-on and explores how clinicians can counter it with science, empathy, and community engagement.
Silent Saboteurs: Managing Endotoxins for Sepsis-Free Sterilization
Invisible yet deadly, endotoxins evade traditional sterilization methods, posing significant risks during routine surgeries. Understanding and addressing their threat is critical for patient safety.
Endoscopes and Lumened Instruments: New Studies Highlight Persistent Contamination Risks
May 7th 2025Two new studies reveal troubling contamination in both new endoscopes and cleaned lumened surgical instruments, challenging the reliability of current reprocessing practices and manufacturer guidelines.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.